Bristol-Myers long-term thesis 'entirely unchanged,' says Citigroup Citigroup said its long-term thesis on shares of Bristol-Myers is "entirely unchanged" after the stock sold off yesterday following safety and efficacy data for Yervoy plus nivolumab. Citi says it has always assumed minimal Yervoy combo use in lung cancer. It reiterates a Buy rating on the stock with a $60 price target.
News For BMY From The Last 14 Days
Check below for free stories on BMY the last two weeks.